Home | About Jay Hochman -Pediatric Gastroenterology Blog | Archives
January 8, 2020 7:02 am
A recent study (AJ Sanyal et al. Hepatology 2019; 70: 1913-27) used prospectively collected data from two large randomized, placebo-controlled phase 2b studies of simtuzumab in patients with either bridging fibrosis (n=217) or compensated cirrhosis (n=258) due to nonalcoholic fatty liver disease (NAFLD). The age range of participants were 48-61 years with median ages of 55 years and 57 years for the two cohorts. All patients had liver biopsies at screening and at weeks 48 and 96.
Key findings:
My take: Among those with advanced liver disease, this study indicates that disease progression/deterioration is rather rapid in about 20%.
Related blog posts:
NY Times: Easy Slopes, Please: Biking the Mountains of Quebec
Posted by gutsandgrowth
Categories: Hepatology
Tags: cirrhosis, fatty liver disease, NAFLD
Mobile Site | Full Site
Get a free blog at WordPress.com Theme: WordPress Mobile Edition by Alex King.
[…] Bad Fatty Liver Disease Can Get Worse Quickly […]
By Progression of Fatty Liver Disease in Children | gutsandgrowth on January 31, 2021 at 9:00 am
[…] Bad Fatty Liver Disease Can Get Worse Quickly […]
By Trends in Liver Diseases: Autoimmune Liver Diseases and Fatty Liver | gutsandgrowth on April 7, 2021 at 7:00 am
[…] Bad Fatty Liver Disease Can Get Worse Quickly […]
By Increased Cancers with Fatty Liver Disease | gutsandgrowth on May 18, 2021 at 7:00 am
[…] Bad Fatty Liver Disease Can Get Worse Quickly […]
By Quantifying the Cancer Risk (Mainly HCC) in Adults with NAFLD | gutsandgrowth on December 3, 2021 at 7:00 am
[…] Bad Fatty Liver Disease Can Get Worse Quickly […]
By How Often Does Liver Disease Develop in Healthy Young Males…Over 65 Year Study Period | gutsandgrowth on January 22, 2022 at 9:00 am